WO2001055724A1 - Method for quantitating autoimmune disease antibody and quantification reagent and quantification kit therefor - Google Patents

Method for quantitating autoimmune disease antibody and quantification reagent and quantification kit therefor Download PDF

Info

Publication number
WO2001055724A1
WO2001055724A1 PCT/JP2000/000394 JP0000394W WO0155724A1 WO 2001055724 A1 WO2001055724 A1 WO 2001055724A1 JP 0000394 W JP0000394 W JP 0000394W WO 0155724 A1 WO0155724 A1 WO 0155724A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
quantification
autoimmune disease
reagent
mouse
Prior art date
Application number
PCT/JP2000/000394
Other languages
French (fr)
Japanese (ja)
Inventor
Tatsuyuki Hachisu
Masaaki Kojima
Tadahiro Kikukawa
Original Assignee
Shibayagi Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shibayagi Co., Ltd filed Critical Shibayagi Co., Ltd
Priority to PCT/JP2000/000394 priority Critical patent/WO2001055724A1/en
Publication of WO2001055724A1 publication Critical patent/WO2001055724A1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Definitions

  • the present invention relates to a novel bacteriostatic and bactericidal composition and a method for using the same, and more particularly to a bacteriostatic and bactericidal composition capable of exhibiting a bactericidal action by mixing substances having a bacteriostatic action. It is not only safe to add directly to foods and drinks, but also safe for dishes, kitchen utensils, cleaning around toilets, and antibacterial bottles.
  • the present invention relates to a bacteriostatic and bactericidal composition that can be used and a method for using the same. Background art
  • autoimmune diseases There are a wide variety of autoimmune diseases, the main examples being autoimmune diseases of the thyroid gland, SLE (systemic erythrothematosus), rheumatoid arthritis, glomerulonephritis, autoimmunity Sexual blood disease.
  • SLE systemic erythrothematosus
  • rheumatoid arthritis rheumatoid arthritis
  • glomerulonephritis autoimmunity Sexual blood disease.
  • the same individual ⁇ suppresses the immune response to the autoantigen in the same individual.
  • abnormal lymphocyte tissue hyperplasia occurs, the immune response becomes abnormal, and the autoreactor reacts with the autoantigen.
  • Autoantibodies are detected.
  • Autoimmune diseases are diseases caused by the immune response to autoantigens.
  • the etiology of the autoimmune disease remains unclear, and elucidation of the mechanism is awaited.
  • An object of the present invention is to administer a drug candidate or a functional food candidate to an autoimmune disease animal and quantify the amount of an antibody such as a rheumatoid factor or an autoantibody in the serum of the administered animal. ing.
  • an object of the present invention is to provide an autoimmune disease antibody quantification method capable of quantifying a rheumatoid factor autoantibody in the serum of a laboratory animal.
  • the present invention relates to an autoimmune disease antibody capable of quantifying the amount of an antibody such as a rheumatoid factor or an autoantibody in the serum of an administered animal using a standard antibody curve. It is intended to provide a measurement system.
  • Another object of the present invention is to provide a quantification reagent that can be used in a method for quantifying an autoimmune disease antibody in a laboratory animal.
  • the present invention provides, as one aspect, a method for quantifying an antibody in an autoimmune disease.
  • the method for quantifying an autoimmune disease antibody according to the present invention is characterized by using a reagent for quantifying an autoimmune disease antibody in a mammalian autoimmune disease animal excluding a human.
  • the autoimmune disease antibody quantification reagent in the method for quantifying an autoimmune disease antibody according to the present invention, includes a mouse rheumatoid factor quantification reagent or a mouse autoimmune disease quantification reagent. It is characterized by using a reagent for quantifying the self antibody.
  • the self is characterized in that a reagent for quantifying anti-mouse single-strand (singlestrand) DNA or a reagent for quantifying anti-mouse double-strand (doub 1 estrand) DNA is used as the reagent for quantifying the self-antibody.
  • a drug candidate or a functional food candidate is administered to an autoimmune disease animal, and
  • a standard antibody curve for the amount of autoimmune disease antibodies is created and the antibody values are quantified.
  • the present invention provides a reagent for quantifying an autoimmune disease antibody, which can be used in the method for quantifying an autoimmune disease antibody.
  • a reagent for quantifying a mouse rheumatoid factor or a reagent for quantifying a mouse autoantibody is provided as the reagent for quantifying an autoimmune disease antibody according to the present invention. I have.
  • the reagent for quantifying a mouse rheumatoid factor is a reagent for quantifying a mouse Ig G type rheumatoid factor or a reagent for quantifying a mouse Ig M type rheumatoid factor.
  • the mouse autoantibody quantification reagent is a mouse anti-ssDNA quantification reagent or a mouse anti-ds DNA quantification reagent.
  • the present invention provides a kit for quantifying an autoimmune disease antibody, which can be used in the above-described method for quantifying an autoimmune disease antibody.
  • the kit for quantifying an autoimmune disease antibody according to the present invention comprises an immoglobulin fraction-immobilized plate, and a mouse for detecting a mouse autoantibody.
  • Mouse consisting of a labeled antibody (second antibody), a standard antibody, a labeling substance, a coloring substance, and a coloring reaction terminator Kit for quantifying antibodies for autoimmune diseases, or mouse anti-double-stranded DNA solid phase Plate, mouse It is characterized in that it is a mouse autoantibody quantification kit comprising a labeled antibody for detection of self-antibody (second antibody), a standard antibody, a label-forming substance, and a coloring reaction terminator.
  • the kit for quantifying an antibody for an autoimmune disease is a mouse IgG type rheumatoid factor, a mouse IgM type rheumatoid factor, a mouse anti-ssDNA, a mouse anti-ssDNA. It is an ELISA kit for anti-ds DNA antibody quantification.
  • FIG. 1 shows a standard antibody curve for quantification of mouse IgG type rheumatoid factor and Ig M type rheumatoid factor.
  • FIG. 2 shows a standard antibody curve for quantification of mouse anti-dsDNA.
  • An autoimmune disease antibody quantification method comprises administering a drug candidate or a functional food candidate to an autoimmune disease animal, and measuring the amount of antibody such as rheumatoid factor or autoantibody in the serum of the administered animal. In quantifying the antibody, a standard antibody curve is created and the antibody value is quantified.
  • the experimental animals, experimental reagents, experimental methods, and the like used in the present invention are those conventionally used to produce antibodies by administering drug candidates or functional food candidates to autoimmune disease animals. Since the description does not change, those skilled in the art are familiar with the description, and the description is omitted here to simplify the description of the specification.
  • an antibody for a standard antibody curve is an MRL / ipr mouse at the age of 20 weeks. Mix the sera collected from two or more animals.
  • a standard antibody curve can be created by creating a dilution series for each positive antibody, determining a unit for each dilution standard, measuring each diluted standard antibody with UV, and obtaining its OD value. it can.
  • a standard antibody curve is created by displaying the OD value of the measurement reagent on the vertical axis and the antibody titer (unit display) on the horizontal axis. I can do it.
  • the antibody titer of the sample can be determined from the standard antibody curve, the antibody titer of the sample can be quantified for each sample. This makes it possible to compare pharmacological tests between facilities, and is useful, for example, in the evaluation of rheumatic pharmacological tests.
  • Example 2 Preparation of standard antibody curve for quantification of mouse IgG type R rheumatoid factor and results of cyclophosphamide administration test.
  • tetramethyltilbenzidine ( ⁇ ⁇ +) + substrate chromogen was added in a quantity of 1001 to each well, and reacted at room temperature for 20 minutes.
  • a reaction stop solution (1 ⁇ sulfuric acid) was added to each well at 100 ⁇ l to stop the reaction.
  • the absorbance of the reaction solution in each well was measured at 450 nm / 600 nm to obtain the average value of the amount of IgG type rheumatoid factor in the mouse serum of each group.
  • Cyclophosphamide (code number: 034-12951, a product of Wako Pure Chemical Industries, Ltd.), which is recognized as an anti-inflammatory substance, was administered in MRL / ipr mouse (Nippon Chills River, Inc.). ), 12 animals, subcutaneously administered 25 mg / kg (lmg / 0.5 ml physiological saline) once a week from the age of 8 weeks, and the mouse IgG G type rheumatism at the age of 20 weeks. Factors were quantitatively measured.
  • Example 3 Preparation of standard antibody curve for quantification of mouse Ig M type M rheumatoid factor and results of cyclophosphamide administration test (see Fig. 1).
  • the immobilized 96-ml plate was washed three times with a washing solution (Twin 20). Each sample and 100 ⁇ l of the standard antibody obtained in Example 1 were added to physiological saline, and this solution was added to each well, and the plate was allowed to react at room temperature for a predetermined time. Then, it was washed three times with the washing solution. Next, HRPconjugatted anti-mouse IgM was added to each well at a rate of 100 z1 and reacted at room temperature for a predetermined time. After the reaction, each well was washed three times with a washing solution.
  • TMB tetramethyltilbenzidine + substrate-chromogen
  • a reaction stop solution (1 ⁇ sulfuric acid) was added to each well in an amount of 100 ⁇ l to stop the reaction.
  • the absorbance of the reaction solution in each well was measured at 450 nm / 600 nm, and the average value of the IgM-type rheumatoid factor in mouse serum of each group was obtained.
  • Cyclophosphamide (code number: 034-12951, manufactured by Wako Pure Chemical Industries, Ltd.), which is recognized as an anti-inflammatory substance, was administered in MRL / ipr mice (Japan 12 mice, 25 mg / kg once a week (8 mg ZO. 5 ml saline) administered once a week from the age of 8 weeks. ⁇ Quantitative measurement of gusset factor was performed.
  • Example 4 Preparation of a standard antibody curve for mouse anti-ds DNA quantification (see FIG. 2) A 96-ml plate with immobilized ds DNA fraction was washed three times with a washing solution (Tween 20). 100 ⁇ l of the standard antibody obtained in Example 1 was added to physiological saline, this solution was added to each well, and the plate was allowed to react at room temperature for a predetermined time. After washing three times with the washing solution, HRP conjugated anti-mouse IgM was added to each well in a volume of 100 ⁇ l, and the mixture was reacted at room temperature for a predetermined time.
  • a washing solution Tween 20
  • the ELISA kit for mouse IgG type R rheumatoid factor quantification has the following composition.
  • the mouse anti-dsDNA quantification ELISA kit has the following composition.
  • the anti-mouse I g G (H + L) turbocharger formic serum was purified by P rotei n G, resulting anti-mouse I g G (H + L) turbocharger formic I g G a HRP (Horse La Defense Mesh Perot Oxidase) to give anti-mouse IgG (H + L) goat IgG—HRP.
  • HRP Hase La Defense Mesh Perot Oxidase
  • the method for quantifying an autoimmune disease antibody includes a reagent for quantifying an autoimmune disease antibody in a mammal with an autoimmune disease excluding human, such as mouse IgG G Rheumatoid factor quantification reagents, such as rheumatoid factor quantification reagents or mouse Ig M type rheumatoid factor quantification reagents.
  • a mouse autoantibody quantification reagent such as a mouse anti-ssDNA quantification reagent or a mouse anti-dsDNA quantification reagent
  • the amount of autoimmune disease antibody is determined using a standard antibody curve. This allows for comparative quantification. Therefore, since the amount of autoimmune disease antibody can be quantified, it is possible to eliminate or reduce the fluctuation of the value between laboratories, and objectively judge the pharmacological experiment for autoimmune disease. It has the advantage of being able to do so.
  • the quantification reagents and quantification kits that can be used in the above-described autoimmune disease antibody quantification method have the effects described above, and are simple to use. It is extremely effective for efficient implementation.
  • the autoimmune disease antibody quantification method and the quantification reagent and the quantification kit according to the present invention having the above-mentioned constitution include, for example, ANA antibody, RNP antibody, Sm antibody, Scl-70 antibody, Mitochondrial antibody, neutrophil cytoplasmic antibody, smooth muscle antibody, skeletal muscle antibody, gastric parietal cell antibody, epidermal component autoantibody, pituitary antibody, cardiolipin antibody, 33–80 antibody , Ss—B / La antibody, ⁇ 0-1 Antibody, centromeric antibody, DNA antibody, thyroglobulin antibody, adrenocortical antibody, ribosome antibody, etc. It can be applied to quantitative measurement of autoimmune disease antibodies.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

An autoimmune disease antibody assay system which comprises administering a candidate for a drug or a candidate for a functional food to an autoimmune disease test animal and expressing an autoimmune disease antibody (a rheumatoid factor in serum, an autoantibody, etc.) level by using a standard antibody curve. Use of this assay system makes it possible to easily and efficiently quantitate an antibody (a rheumatoid factor in serum, an autoantibody, etc.) in the serum of an animal to which a candidate for a drug or a candidate for a functional food is administered.

Description

明 細 書 自 己免疫疾患抗体定量方法およびその定量用試薬な らびに定量用キッ 卜 技術分野  Description Method for quantification of autoimmune disease antibody, reagent for quantification thereof, and kit for quantification
本発明は、 新規な制菌ならびに殺菌用組成物およびその使用方法に関し、 更に詳細には、 制菌作用を有する物質同士を混合することによって殺菌作用 を示すことができる制菌ならびに殺菌用組成物であって、 飲食品などに対し て直接添加しても安全であるばかりでなく 、 食器類、 厨房用具や、 トイ レま わりの洗浄用などにも、 または抗菌 卜などと しても安全に使用すること ができる制菌ならびに殺菌用組成物およびその使用方法に関するものである。 背景技術  The present invention relates to a novel bacteriostatic and bactericidal composition and a method for using the same, and more particularly to a bacteriostatic and bactericidal composition capable of exhibiting a bactericidal action by mixing substances having a bacteriostatic action. It is not only safe to add directly to foods and drinks, but also safe for dishes, kitchen utensils, cleaning around toilets, and antibacterial bottles. The present invention relates to a bacteriostatic and bactericidal composition that can be used and a method for using the same. Background art
自 己免疫疾患には多岐な症例があ り 、 主たる疾患例と して甲状腺の 自 己免疫疾患、 S L E (全身性エ リ 卜テマ トーデス)、 リ ウマチ様関節 炎、 糸球体腎炎、 自 己免疫性血液疾患等がある。 一般には、 同一個体 內で自 己抗原に対する免疫応答は抑制 されているが、 免疫疾患では異 常な リ ンパ系組織の増生が起こ り 、 免疫応答が異常にな り 、 自 己抗原 と反応する 自 己抗体が検出される。 自 己免疫疾患は、 自 己抗原に対す る免疫応答が原因と なって起こ る疾患であるが、 成因については不明 な点が多いため、 機序解明が待たれている。  There are a wide variety of autoimmune diseases, the main examples being autoimmune diseases of the thyroid gland, SLE (systemic erythrothematosus), rheumatoid arthritis, glomerulonephritis, autoimmunity Sexual blood disease. In general, the same individual は suppresses the immune response to the autoantigen in the same individual.However, in an immune disease, abnormal lymphocyte tissue hyperplasia occurs, the immune response becomes abnormal, and the autoreactor reacts with the autoantigen. Autoantibodies are detected. Autoimmune diseases are diseases caused by the immune response to autoantigens. However, the etiology of the autoimmune disease remains unclear, and elucidation of the mechanism is awaited.
そこで、 ヒ 卜 と 同様な自 己免疫疾患を 自然発症する実験動物や、 人 ェ的に炎症を発症させたマ ウス · ラ ッ ト を使用 して 自 己免疫疾患の機 序解明の研究が今日進められている。 発明の開示 Therefore, research on the elucidation of the mechanism of autoimmune diseases using experimental animals that naturally develop autoimmune diseases similar to humans and mouse rats that have artificially developed inflammation has been carried out today. Is underway. Disclosure of the invention
この発明は、 自 己免疫疾患動物に薬物候補または機能性食品候補を 投与 して、 投与された動物の血清中の リ ゥマチ因子や自 己抗体な どの 抗体量を定量する こ と を 目的と している。  An object of the present invention is to administer a drug candidate or a functional food candidate to an autoimmune disease animal and quantify the amount of an antibody such as a rheumatoid factor or an autoantibody in the serum of the administered animal. ing.
更に詳細には、 こ の発明は、 実験動物の血清中の リ ゥマチ因子ゃ自 己抗体を定量する こ と ができ る 自 己免疫疾患抗体定量方法を提供する こ と を 目 的 と している。 つま り 、 こ の発明は、 投与された動物の血清 中の リ ゥマチ因子や自 己抗体な どの抗体量を、 標準抗体曲線を使用 し て数値化をする こ と ができ る 自 己免疫疾患抗体測定系を提供する こ と を目的と している。  More specifically, an object of the present invention is to provide an autoimmune disease antibody quantification method capable of quantifying a rheumatoid factor autoantibody in the serum of a laboratory animal. . In other words, the present invention relates to an autoimmune disease antibody capable of quantifying the amount of an antibody such as a rheumatoid factor or an autoantibody in the serum of an administered animal using a standard antibody curve. It is intended to provide a measurement system.
また、 こ の発明は、 実験動物の自 己免疫疾患抗体定量方法に使用す る こ とができ る定量用試薬を提供する こ と を目的と している。  Another object of the present invention is to provide a quantification reagent that can be used in a method for quantifying an autoimmune disease antibody in a laboratory animal.
更に、 こ の発明は実験動物の 自 己免疫疾患抗体定量用キ ッ 卜 を提供 する こ と を目的と している。  Further, it is an object of the present invention to provide a kit for quantifying autoimmune disease antibodies in experimental animals.
こ の発明の上記目的を達成するために、 こ の発明は、 1 つの態様と して、 自 己免疫疾患抗体定量方法を提供する。  In order to achieve the above object of the present invention, the present invention provides, as one aspect, a method for quantifying an antibody in an autoimmune disease.
更に詳細には、 こ の発明に係る 自 己免疫疾患抗体定量方法は、 ヒ 卜 を除く 哺乳動物の自 己免疫疾患動物の自 己免疫疾患抗体定量用試薬を 使用する こ と を特徴とする。  More specifically, the method for quantifying an autoimmune disease antibody according to the present invention is characterized by using a reagent for quantifying an autoimmune disease antibody in a mammalian autoimmune disease animal excluding a human.
こ の発明の好ま しい実施態様においては、 こ の発明に係る 自 己免疫 疾患抗体定量方法において、 該自 己免疫疾患抗体定量用試薬と して、 マ ウス リ ゥマチ因子定量用試薬またはマ ウス 自 己抗体定量用試薬を使 用する こ と を特徴とする。  In a preferred embodiment of the present invention, in the method for quantifying an autoimmune disease antibody according to the present invention, the autoimmune disease antibody quantification reagent includes a mouse rheumatoid factor quantification reagent or a mouse autoimmune disease quantification reagent. It is characterized by using a reagent for quantifying the self antibody.
こ の発明の更に好ま しい実施態様においては、 該マ ウス リ ゥマチ因 子定量用試薬と して、 マ ウ ス I g G型 リ ウマチ因子定量用試薬または マ ウス I g M型 リ ウマチ因子定量用試薬を使用する こ と。 また、 該自 己抗体定量用試薬と して、 抗マ ウス一本鎖 ( s i n g l e s t r a n d ) D N A定量用試薬または抗マ ウス二本鎖 ( d o u b 1 e s t r a n d ) D N A定量用試薬を使用する こ と を特徴とする。 In a further preferred correct implementation of the invention in this, as a該Ma mortar Li Umachi factor quantitative reagent, Ma U scan I g G type rheumatism factor quantitative reagent or mouse I g M type rheumatism factor quantitatively Use reagents for In addition, the self It is characterized in that a reagent for quantifying anti-mouse single-strand (singlestrand) DNA or a reagent for quantifying anti-mouse double-strand (doub 1 estrand) DNA is used as the reagent for quantifying the self-antibody.
更にまた、 この発明の好ま しい実施態様においては、 この発明に係 る 自 己免疫疾患抗体定量方法において、 自 己免疫疾患動物に薬物候補 または機能性食品候補を投与して、 投与された動物の血清中の リ ゥマ チ因子ゃ自 己抗体などの自 己免疫疾患抗体量を定量するに当たって、 かかる 自 己免疫疾患抗体量の標準抗体曲線を作成 し、 抗体値を数値化 する こ と を特徴とする。  Furthermore, in a preferred embodiment of the present invention, in the method for quantifying an autoimmune disease antibody according to the present invention, a drug candidate or a functional food candidate is administered to an autoimmune disease animal, and In quantifying the amount of autoimmune disease antibodies such as rheumatoid factor autoantibodies in serum, a standard antibody curve for the amount of autoimmune disease antibodies is created and the antibody values are quantified. And
こ の発明は、 別の態様と して、 上記自 己免疫疾患抗体定量方法に使 用する こ とができ る 自 己免疫疾患抗体定量用試薬を提供する。  In another aspect, the present invention provides a reagent for quantifying an autoimmune disease antibody, which can be used in the method for quantifying an autoimmune disease antibody.
こ の発明の好ま しい実施態様においては、 こ の発明に係る 自 己免疫 疾患抗体定量用試薬と して、 マ ウ ス リ ゥマチ因子定量用試薬またはマ ウス 自 己抗体定量用試薬を提供している。  In a preferred embodiment of the present invention, a reagent for quantifying a mouse rheumatoid factor or a reagent for quantifying a mouse autoantibody is provided as the reagent for quantifying an autoimmune disease antibody according to the present invention. I have.
こ の発明の更に好ま しい実施態様においては、 上記マ ウス リ ゥマチ 因子定量用試薬がマ ウス I g G型 リ ゥマチ因子定量用試薬またはマ ウ ス I g M型 リ ウマチ因子定量用試薬である こ と 、 また、 上記マウス 自 己抗体定量用試薬がマ ウス抗 s s D N A定量用試薬またはマ ウス抗 d s D N A定量用試薬である こ と を特徴とする。  In a further preferred embodiment of the present invention, the reagent for quantifying a mouse rheumatoid factor is a reagent for quantifying a mouse Ig G type rheumatoid factor or a reagent for quantifying a mouse Ig M type rheumatoid factor. Also, the mouse autoantibody quantification reagent is a mouse anti-ssDNA quantification reagent or a mouse anti-ds DNA quantification reagent.
こ の発明は、 更に別の態様と して、 上記自 己免疫疾患抗体定量方法 に使用する こ と ができ る 自 己免疫疾患抗体定量用キッ トを提供する。 こ の発明の好ま しい実施態様においては、 こ の発明に係る 自 己免疫 疾患抗体定量用キ ッ 卜が、 ィ ムノ グロ ブ リ ン分画固相化プレー 卜 と 、 マ ウス 自 己抗体検出用標識抗体 (第二抗体) と 、 標準抗体と 、 標識物 発色物質と 、 発色反応停止剤とからなるマ ウ ス 自 己免疫疾患抗体定量 用キッ ト、 または、 マ ウス抗ニ本鎖 D N A固相化プレー ト、 マ ウス 自 己抗体検出用標識抗体 (第二抗体) と 、 標準抗体と 、 標識物発色物質 と 、 発色反応停止剤と からなるマウス 自 己抗体定量用キ ッ トである こ と を特徴とする。 In another aspect, the present invention provides a kit for quantifying an autoimmune disease antibody, which can be used in the above-described method for quantifying an autoimmune disease antibody. In a preferred embodiment of the present invention, the kit for quantifying an autoimmune disease antibody according to the present invention comprises an immoglobulin fraction-immobilized plate, and a mouse for detecting a mouse autoantibody. Mouse consisting of a labeled antibody (second antibody), a standard antibody, a labeling substance, a coloring substance, and a coloring reaction terminator Kit for quantifying antibodies for autoimmune diseases, or mouse anti-double-stranded DNA solid phase Plate, mouse It is characterized in that it is a mouse autoantibody quantification kit comprising a labeled antibody for detection of self-antibody (second antibody), a standard antibody, a label-forming substance, and a coloring reaction terminator.
こ の発明の更に好ま しい実施態様においては、 上記自 己免疫疾患 抗体定量用キ ッ 卜がマ ウス I g G型 リ ゥマチ因子, マウス I g M型 リ ゥマチ因子, マウス抗 s s D N A, マ ウス抗 d s D N A抗体定量用 E L I S Aキッ 卜である こ と を特徴とする。  In a further preferred embodiment of the present invention, the kit for quantifying an antibody for an autoimmune disease is a mouse IgG type rheumatoid factor, a mouse IgM type rheumatoid factor, a mouse anti-ssDNA, a mouse anti-ssDNA. It is an ELISA kit for anti-ds DNA antibody quantification.
この発明のその他の 目 的、 特長ならびに利点は、 添付図面を参照 し た下記明細書の記載によ り 明白 と なろ う„ 図面の簡単な説明  Other objects, features, and advantages of the present invention will become apparent from the following description with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
図 1 は、 マ ウス I g G型リ ウマチ因子並びに I g M型 リ ウマチ因子 定量用標準抗体曲線を示す。  FIG. 1 shows a standard antibody curve for quantification of mouse IgG type rheumatoid factor and Ig M type rheumatoid factor.
図 2 は、 マウス抗 d s D N A定量用標準抗体曲線を示す。 発明を実施するための最良の形態  FIG. 2 shows a standard antibody curve for quantification of mouse anti-dsDNA. BEST MODE FOR CARRYING OUT THE INVENTION
この発明に係る 自 己免疫疾患抗体定量方法は、 自 己免疫疾患動物に 薬物候補または機能性食品候補を投与 して、 投与された動物の血清中 の リ ゥマチ因子や自 己抗体などの抗体量を定量するに当たって、 標準 抗体曲線を作成し、 抗体値を数値化する こ とから構成されている。 なお、 この発明において使用 される実験動物、 実験試薬、 実験方法 などは、 従来から 自 己免疫疾患動物に薬物候補または機能性食品候補 を投与 して抗体を産生するために慣用 されている もの と変わらないの で、 当業者であれば熟知されているので、 こ こでは明細書の記载を簡 略にするために記載を省略する こ と にする。  An autoimmune disease antibody quantification method according to the present invention comprises administering a drug candidate or a functional food candidate to an autoimmune disease animal, and measuring the amount of antibody such as rheumatoid factor or autoantibody in the serum of the administered animal. In quantifying the antibody, a standard antibody curve is created and the antibody value is quantified. The experimental animals, experimental reagents, experimental methods, and the like used in the present invention are those conventionally used to produce antibodies by administering drug candidates or functional food candidates to autoimmune disease animals. Since the description does not change, those skilled in the art are familiar with the description, and the description is omitted here to simplify the description of the specification.
次に、 自 己免疫疾患抗体定量方法に使用する標準抗体曲線について 記載する。 Next, the standard antibody curve used for autoimmune disease antibody quantification Describe.
例えば、 マウス I g G型 リ ゥマチ因子定量用 E L I S A キッ トを使 用する 自 己免疫疾患抗体定量方法において、 標準抗体曲線用の抗体と しては、 2 0週令時の M R L / i p r マ ウス 2 匹以上から採血 した血 清を混ぜて使用する。 ポジティ ブ抗体の各希釈系列を作り 希釈標準品 毎にュニ ッ ト を決め、 各希釈標準抗体を U Vで測定 し、 その O D値を 得る こ と によ り標準抗体曲線を作成する こ とができ る。 つま り 、 図 1 に示すよ う に、 標準抗体曲線は、 縦軸に測定試薬の O D値を、 また横 軸に抗体価 (ユニ ッ ト表示) を表示する こ と によ り 作成する こ と がで きる。 この標準抗体曲線よ り検体の抗体価を決める こ とができ るので、 検体の抗体価を検体別に数値化ができ る。 したがって、 施設間での薬 理試験の比較をする こ と が可能と な り 、 例えばリ ユーマチ薬理試験の 評価と しても有用である。  For example, in an autoimmune disease antibody quantification method using an ELISA kit for quantification of a mouse IgG type R rheumatoid factor, an antibody for a standard antibody curve is an MRL / ipr mouse at the age of 20 weeks. Mix the sera collected from two or more animals. A standard antibody curve can be created by creating a dilution series for each positive antibody, determining a unit for each dilution standard, measuring each diluted standard antibody with UV, and obtaining its OD value. it can. In other words, as shown in Fig. 1, a standard antibody curve is created by displaying the OD value of the measurement reagent on the vertical axis and the antibody titer (unit display) on the horizontal axis. I can do it. Since the antibody titer of the sample can be determined from the standard antibody curve, the antibody titer of the sample can be quantified for each sample. This makes it possible to compare pharmacological tests between facilities, and is useful, for example, in the evaluation of rheumatic pharmacological tests.
この発明を実施例によ り 更に詳細に説明する。  The present invention will be described in more detail with reference to examples.
実施例 1 : 標準抗体の作製 Example 1: Preparation of standard antibody
M R L / i p r マウス (日本チヤ一ルス リ バ一株式会社製)、 d\ 2 0週令時 3 0 匹から全血採血を行い、 定法によ り 血清を分離 した。 分 離した血清を さ らに純度を上げる為に遠心分離 ( 1 0, 000 G、 3 0 分) して、 0. 22 / mフィルターろ過 した。 希釈液を用い 1 0倍に希釈 し標 準抗体溶液と した。 1 0倍に希釈 した標準抗体溶液を さ らに希釈液で 6段階に希釈して 7濃度の標準曲線作製用標準抗体と した。  Whole blood was collected from 30 MRL / ip r mice (manufactured by Nippon Charls River Co., Ltd.) at d \ 20 weeks of age, and serum was separated by a standard method. The separated serum was centrifuged (10,000 G, 30 minutes) to further increase the purity, and filtered through a 0.22 / m filter. It was diluted 10-fold with a diluent to obtain a standard antibody solution. The 10-fold diluted standard antibody solution was further diluted in 6 steps with a diluent to obtain a standard antibody for preparing a standard curve having 7 concentrations.
また、 1 0倍希釈前の血清中の生化学検査を行い 2 次標準抗体作製 の基礎資料と した。  In addition, a serum biochemical test before 10-fold dilution was performed and used as basic data for preparation of a secondary standard antibody.
実施例 2 : マ ウス I g G型 リ ゥマチ因子定量用標準抗体曲線の作製と シク ロホスフア ミ ド投与試験結果。 Example 2: Preparation of standard antibody curve for quantification of mouse IgG type R rheumatoid factor and results of cyclophosphamide administration test.
ィ ムノ グロブ リ ン分画固相化 9 6 ゥエルプレー トを洗浄液 (ツイ 一 ン 2 0 ) で 3 回洗浄した。 各サンプルと 、 実施例 1 で得た標準抗体と を 1 0 0 // 1 づっ生理的食塩水に添加 し、 こ の溶液を各ゥエルに添加 し て、 プレー ト を室温で所定時間反応させた。 その後、 洗浄液で 3 回洗 浄した。 次いで、 H R P c o n j u g a t e d抗マ ウス I g Gを各 ゥ エルに対 して 1 0 0 μ 1 づっ添加 して、 室温で所定時間反応させた。 反応後、 各ゥエルを洗浄液で 3 回洗浄 した。 洗浄後、 更に、 テ ト ラ メ チルベンチジン ( Τ Μ Β ) +基質一 ク ロモーゲンを各ゥエルに対して 1 0 0 1 づっ添加 して、 室温で 2 0 分間反応させた。 次いで、 反応 停止液 ( 1 Ν硫酸) を各ゥエルに 1 0 0 μ 1 づっ添加 して、 反応を停 止させた。 各ゥエルの反応液を 4 5 0 n m / 6 0 0 n mの吸光度を測 定して、 それぞれのグループのマ ウス血清中 I g G型 リ ウマチ因子量 の平均値を得た。 Immobilize iminoglobulin fraction on solid phase 96 Washed three times with 20). Each sample and the standard antibody obtained in Example 1 were added to physiological saline in a ratio of 100 // 1 and this solution was added to each well, and the plate was allowed to react at room temperature for a predetermined time. . Then, it was washed three times with the washing solution. Next, 100 μl of HRP conjugated anti-mouse IgG was added to each well and allowed to react at room temperature for a predetermined time. After the reaction, each well was washed three times with a washing solution. After washing, tetramethyltilbenzidine (Τ Τ +) + substrate chromogen was added in a quantity of 1001 to each well, and reacted at room temperature for 20 minutes. Next, a reaction stop solution (1 停止 sulfuric acid) was added to each well at 100 μl to stop the reaction. The absorbance of the reaction solution in each well was measured at 450 nm / 600 nm to obtain the average value of the amount of IgG type rheumatoid factor in the mouse serum of each group.
抗炎症物質と して認知されている シク ロ ホスフ ア ミ ド (和光純薬株 式会社製 コー ド番号 ; 034 12951 ) 投与試験は、 M R L / i p r マ ウ ス (日本チヤ一ルス リ バ一株式会社製)、 、 1 2 匹、 8週令から週 1 回 2 5 m g / k g を皮下投与 ( l m g / 0 . 5 m l 生理食塩水) し、 2 0 週令時のマウス I g G型リ ゥマチ因子の定量測定を行った。  Cyclophosphamide (code number: 034-12951, a product of Wako Pure Chemical Industries, Ltd.), which is recognized as an anti-inflammatory substance, was administered in MRL / ipr mouse (Nippon Chills River, Inc.). ), 12 animals, subcutaneously administered 25 mg / kg (lmg / 0.5 ml physiological saline) once a week from the age of 8 weeks, and the mouse IgG G type rheumatism at the age of 20 weeks. Factors were quantitatively measured.
その結果は次の通り である。  The results are as follows.
Figure imgf000007_0001
Figure imgf000007_0001
M R Lマ ウス ( 2 0週令) にシク ロ ホスフ ア ミ ド ( 2 5 m g Z K g ) 投与試験結果 R F— I g Gの ュニッ ト換算値 Cyclophosphamide (25 mg ZK g) administration test results to MRL mouse (20 weeks old) RF—unit value of IgG
平均値 ― (mU)  Average value-(mU)
0. 6 7 2 7 8 0  0.6 6 7 2 7 8 0
実施例 3 : マウス I g M型 リ ウマチ因子定量用標準抗体曲線の作製と シク ロホス フア ミ ド投与試験結果 (図 1 参照)。 Example 3: Preparation of standard antibody curve for quantification of mouse Ig M type M rheumatoid factor and results of cyclophosphamide administration test (see Fig. 1).
ィ ムノ グロ ブ リ ン分画固相化 9 6 ゥエルプレー ト を洗浄液 (ツイ 一 ン 2 0 ) で 3 回洗浄した。 各サンプルと 、 実施例 1 で得た標準抗体と を 1 0 0 μ 1 づっ生理的食塩水に添加 し、 こ の溶液を各 ゥエルに添加 して、 プレー ト を室温で所定時間反応させた。 その後、 洗浄液で 3 回 洗浄した。 次いで、 H R P c o n j u g a t e d抗マ ウス I g Mを各 ゥエルに対して 1 0 0 z 1 づっ添加 して、 室温で所定時間反応させた。 反応後、 各ゥエルを洗浄液で 3 回洗浄した。 洗浄後、 更に、 テ ト ラメ チルベンチジン ( T M B ) +基質一 ク ロ モー ゲンを各ゥエルに対 して 1 0 0 1 づっ添加 して、 室温で 2 0分間反応させた。 次いで、 反応 停止液 ( 1 Ν硫酸) を各ゥエルに 1 0 0 μ 1 づっ添加 して、 反応を停 止させた。 各ゥエルの反応液を 4 5 0 n m/ 6 0 0 n mの吸光度を測 定して、 それぞれのグループのマ ウス血清中 I g M型 リ ゥマチ因子量 の平均値を得た。  The immobilized 96-ml plate was washed three times with a washing solution (Twin 20). Each sample and 100 μl of the standard antibody obtained in Example 1 were added to physiological saline, and this solution was added to each well, and the plate was allowed to react at room temperature for a predetermined time. Then, it was washed three times with the washing solution. Next, HRPconjugatted anti-mouse IgM was added to each well at a rate of 100 z1 and reacted at room temperature for a predetermined time. After the reaction, each well was washed three times with a washing solution. After washing, tetramethyltilbenzidine (TMB) + substrate-chromogen was added to each well in a quantity of 1001, and reacted at room temperature for 20 minutes. Next, a reaction stop solution (1Ν sulfuric acid) was added to each well in an amount of 100 μl to stop the reaction. The absorbance of the reaction solution in each well was measured at 450 nm / 600 nm, and the average value of the IgM-type rheumatoid factor in mouse serum of each group was obtained.
抗炎症物質と して認知されている シク ロ ホス フ ア ミ ド (和光純薬 株式会社製 コー ド番号 ; 034-12951) 投与試験は、 M R L / i p r マ ウ ス (日本チヤ一ルス リ バ一株式会社製)、 、 1 2 匹、 8週令から週 1 回 2 5 m g / k g を皮下投与 (lm g Z O . 5 m l 生理食塩水) し、 2 0週令時のマウス I g M型リ ゥマチ因子の定量測定を行った。  Cyclophosphamide (code number: 034-12951, manufactured by Wako Pure Chemical Industries, Ltd.), which is recognized as an anti-inflammatory substance, was administered in MRL / ipr mice (Japan 12 mice, 25 mg / kg once a week (8 mg ZO. 5 ml saline) administered once a week from the age of 8 weeks.定量 Quantitative measurement of gusset factor was performed.
その結果は次の通り である。 表 2 The results are as follows. Table 2
Figure imgf000009_0001
Figure imgf000009_0001
M R L マ ウス ( 2 0週令) にシク ロ ホス フ ア ミ ド ( 2 5 m g Z K g ) 投与試験結果 Cyclophosphamide (25 mg ZKg) administration test results to MRL mice (20 weeks old)
R F — I g M の ユニッ ト換算値  R F — Unit value of Ig M
平均値 (mU)  Average value (mU)
0 . 6 5 2 3 1 3  0. 6 5 2 3 1 3
実施例 4 : マ ウス抗 d s D N A定量用標準抗体曲線の作成 (図 2参照 d s D N A分画固相化 9 6 ゥエルプレー 卜を洗浄液 (ツイ ー ン 2 0 ) で 3 回洗浄 した。 各サンプルと 、 実施例 1 で得た標準抗体と を 1 0 0 μ 1 づっ生理的食塩水に添加 し、 こ の溶液を各ゥエルに添加 して、 プ レ— トを室温で所定時間反応させた。 その後、 洗浄液で 3 回洗浄した。 次いで、 H R P c o n j u g a t e d 抗マ ウス I g Mを各ゥエルに対 して 1 0 0 μ 1 づっ添加 して、 室温で所定時間反応させた。 反応後、 各ゥエルを洗浄液で 3 回洗浄した。 洗浄後、 更に、 テ ト ラ メ チルベン チジン ( Τ Μ Β ) +基質一 ク ロモーゲンを各 ウエノレに対 して 1 0 0 μ 1 づっ添加 して、 室温で 2 0分間反応させた。 次いで、 反応停止液 ( 1 Ν硫酸) を各ゥエルに 1 0 Ο μ ΐ づっ添加 して、 反応を停止させた。 各ゥエルの反応液を 4 5 0 n m / 6 0 0 n mの吸光度を測定して、 そ れぞれのグループのマウス血清中抗 d s D N A量の平均値を得た。 Example 4: Preparation of a standard antibody curve for mouse anti-ds DNA quantification (see FIG. 2) A 96-ml plate with immobilized ds DNA fraction was washed three times with a washing solution (Tween 20). 100 μl of the standard antibody obtained in Example 1 was added to physiological saline, this solution was added to each well, and the plate was allowed to react at room temperature for a predetermined time. After washing three times with the washing solution, HRP conjugated anti-mouse IgM was added to each well in a volume of 100 μl, and the mixture was reacted at room temperature for a predetermined time. After washing, add tetramethyl benzylbenzidine (Τ Μ Β) + substrate chromogen (100 μl / well) to each well, and react at room temperature for 20 minutes. Next, add 10 µl of a reaction stop solution (1 µsulfuric acid) to each well. The reaction solution in each well was measured for absorbance at 450 nm / 600 nm to obtain the average amount of anti-ds DNA in mouse serum of each group. Was.
その結果は次の通り である。 表 3 The results are as follows. Table 3
Figure imgf000010_0001
実施例 5 :
Figure imgf000010_0001
Example 5:
マウス I g G型 リ ゥマチ因子定量用 E L I S Aキ ッ ト は次の構成か らなっている。  The ELISA kit for mouse IgG type R rheumatoid factor quantification has the following composition.
ィムノ グロブリ ン分画固相 9 6 ゥエルプレー ト : 1 枚  Imnoglobulin fractionated solid phase 96 6 ゥ el plate: 1 piece
マ ウス 自 己抗体検出用酵素標識抗体 (第二抗体) :  Mouse Enzyme-labeled antibody for detection of self-antibody (second antibody):
2 0 μ \ Ζ本、 1 本  2 0 μ \ Ζ, 1
マ ウス I g G型リ ゥマチ因子標準抗体 :  Mouse Ig type G rheumatoid factor standard antibody:
6 ( 7 ) 濃度、 5 0 0 1 本、 1 本  6 (7) concentration, 500 1 bottle, 1 bottle
標識物発色物質 (T M B ) : I S m l Z本、 1 本  Labeling substance (T M B): I S ml Z, 1
発色反応停止剤 ( 1 N硫酸) : 1 2 m l /本、 1 本  Coloring reaction terminator (1N sulfuric acid): 12 ml / bottle, 1 bottle
検体希釈液 ( P B S系) : 5 0 ( 6 0 ) m l /本、 1 本 9 6 ゥエルプレー ト洗浄溶液 : 5 0 m l Z本、 1 本  Sample diluent (PBS system): 50 (60) ml / bottle, 1 bottle 96 ゥ Elplate washing solution: 50 ml Z, 1 bottle
実施例 6 : Example 6:
マウス抗 d s D N A定量用 E L I S Aキ ッ トは次の構成からなって いる。  The mouse anti-dsDNA quantification ELISA kit has the following composition.
d s D N A固相 9 6 ゥエルプレー ト : 1 枚  d s D N A Solid phase 9 6 ゥ El plate: 1 piece
マウス 自 己抗体検出用酵素標識抗体 (第二抗体) :  Mouse Enzyme-labeled antibody for detection of autoantibody (second antibody):
2 0 μ 1 /本、 1 本  20 μ 1 / book, 1 book
マウス d s D N A標準抗体 :  Mouse dsDNA standard antibody:
6 ( 7 ) 濃度、 5 0 0 μ 1 Ζ本、 1 本 標識物発色物質 ( TM B ) : 1 2 m l /本、 1 本 6 (7) Concentration, 500 μl 1 bottle, 1 bottle Labeled substance (TMB): 12 ml / bottle, 1 bottle
発色反応停止剤 ( 1 N硫酸) : 1 2 m l / 本、 1 本  Coloring reaction terminator (1 N sulfuric acid): 12 ml / bottle, 1 bottle
検体希釈液 ( P B S系) : 5 0 ( 6 0 ) m l Z本、 1 本  Sample diluent (PBS system): 50 (60) ml Z, 1
9 6 ゥエルプレー ト洗浄溶液 : 5 0 m l Z本、 1 本  9 6 ゥ El plate cleaning solution: 50 ml Z, 1
実施例 7 : 酵素標識抗体の作製 Example 7: Preparation of enzyme-labeled antibody
抗マ ウス I g G ( H + L ) ャギ血清を P r o t e i n G で精製 し、 得られた抗マ ウス I g G ( H + L ) ャギ I g G を H R P (ホース ラデ ッシュぺロ ォキシダーゼ) で常法に従って標識する と 、 抗マ ウス I g G ( H + L ) ャギ I g G— H R P が得られた。 マ ウス血清中の非特異 物質を除去するために常法に従って精製 して、 酵素標識抗体を作製 し た。 発明の効果 The anti-mouse I g G (H + L) turbocharger formic serum was purified by P rotei n G, resulting anti-mouse I g G (H + L) turbocharger formic I g G a HRP (Horse La Defense Mesh Perot Oxidase) to give anti-mouse IgG (H + L) goat IgG—HRP. Purification was performed according to a conventional method to remove non-specific substances from mouse serum, and an enzyme-labeled antibody was prepared. The invention's effect
前述 したよ う に、 こ の発明に係る 自 己免疫疾患抗体定量方法は、 ヒ トを除く 哺乳動物の自 己免疫疾患動物の自 己免疫疾患抗体定量用試薬、 例えば、 マ ウス I g G型 リ ウマチ因子定量用試薬またはマ ウ ス I g M 型 リ ゥマチ因子定量用試薬などのマ ウ ス リ ゥマチ因子定量用試薬。 ま たは、 マウス抗 s s D N A定量用試薬またはマウス抗 d s D N A定量 用試薬などのマ ウ ス 自 己抗体定量用試薬などを使用 して、 標準抗体曲 線を用いて 自 己免疫疾患抗体量を比較定量する こ と ができ る よ う にな つている。 したがって、 自 己免疫疾患抗体量を数値化でき るので、 実 験施設間での数値の変動を無く した り または少なく する こ と ができ る ので、 自 己免疫疾患の薬理実験を客観的に判断でき る と い う利点があ る。  As described above, the method for quantifying an autoimmune disease antibody according to the present invention includes a reagent for quantifying an autoimmune disease antibody in a mammal with an autoimmune disease excluding human, such as mouse IgG G Rheumatoid factor quantification reagents, such as rheumatoid factor quantification reagents or mouse Ig M type rheumatoid factor quantification reagents. Alternatively, using a mouse autoantibody quantification reagent such as a mouse anti-ssDNA quantification reagent or a mouse anti-dsDNA quantification reagent, the amount of autoimmune disease antibody is determined using a standard antibody curve. This allows for comparative quantification. Therefore, since the amount of autoimmune disease antibody can be quantified, it is possible to eliminate or reduce the fluctuation of the value between laboratories, and objectively judge the pharmacological experiment for autoimmune disease. It has the advantage of being able to do so.
前述 した 自 己免疫疾患抗体定量方法に使用でき る定量用試薬な らび に定量用キ ッ トは、 上記のよ う な効果の他に、 上記定量方法を簡便で かつ効率よ く 実施するのに極めて有効である。 The quantification reagents and quantification kits that can be used in the above-described autoimmune disease antibody quantification method have the effects described above, and are simple to use. It is extremely effective for efficient implementation.
前述 したよ う な構成からなる この発明に係る 自 己免疫疾患抗体定量 方法およびその定量用試薬ならびに定量用キッ トは、 例えば、 A N A 抗体, R N P抗体、 S m抗体、 S c l — 7 0抗体、 ミ ト コ ン ド リ ア抗 体、 好中球細胞質抗体、 平滑筋抗体骨格筋抗体、 胃壁細胞抗体、 表皮 成分自 己抗体、 下垂体抗体、 カルジォ リ ピン抗体、 3 3 —八 1¾ 0抗 体、 s s — B / L a 抗体、 】 0 — 1 抗体、 セン ト ロ メ ァ抗体、 D N A 抗体、 サイ ロ グロ ブ リ ン抗体、 副腎皮質抗体、 リ ボゾーム抗体などの ヒ ト を除く 哺乳動物の自 己免疫疾患抗体の定量測定に応用する こ と が できる。  The autoimmune disease antibody quantification method and the quantification reagent and the quantification kit according to the present invention having the above-mentioned constitution include, for example, ANA antibody, RNP antibody, Sm antibody, Scl-70 antibody, Mitochondrial antibody, neutrophil cytoplasmic antibody, smooth muscle antibody, skeletal muscle antibody, gastric parietal cell antibody, epidermal component autoantibody, pituitary antibody, cardiolipin antibody, 33–80 antibody , Ss—B / La antibody,】 0-1 Antibody, centromeric antibody, DNA antibody, thyroglobulin antibody, adrenocortical antibody, ribosome antibody, etc. It can be applied to quantitative measurement of autoimmune disease antibodies.

Claims

1 請 求 の 範 囲 1 Scope of request
1 . 自 己免疫疾患抗体定量方法と して、 ヒ ト を除く 哺乳動物の自 己 免疫疾患動物の自 己免疫疾患抗体定量用試薬を使用する こ と を特徴と する 自 己免疫疾患抗体定量方法。 1. An autoimmune disease antibody quantification method characterized by using a reagent for quantifying autoimmune disease antibodies in mammals excluding humans, as an autoimmune disease antibody quantification method. .
2 . 請求の範囲第 1 項に記載する 自 己免疫疾患抗体定量方法におい て、 前記自 己免疫疾患抗体定量用試薬と して、 マ ウ ス リ ウマチ因子定 量用試薬またはマ ウス 自 己抗体定量用試薬を使用する こ と を特徴とす る 自 己免疫疾患抗体定量方法。  2. The autoimmune disease antibody quantification method according to claim 1, wherein the autoimmune disease antibody quantification reagent is a mouse rheumatoid factor quantification reagent or a mouse autoantibody. An autoimmune disease antibody quantification method characterized by using a quantification reagent.
3 . 請求の範囲第 1 項または第 2 項に記載する 自 己免疫疾患抗体定 量方法において、 前記マ ウス リ ウマチ因子定量用試薬がマ ウ ス I g G 型リ ウマチ因子 ( R F — I g G ) 定量用試薬またはマ ウス I g M型 リ ゥマチ因子 ( R F — I g M) 定量用試薬である こ と を特徴とする 自 己 免疫疾患抗体定量方法。  3. The method for quantifying an antibody to an autoimmune disease according to claim 1 or 2, wherein the reagent for quantifying murine rheumatoid factor is mouse Ig G-type rheumatoid factor (RF—Ig). G) An autoimmune disease antibody quantification method, characterized in that the reagent is a quantification reagent or a mouse IgM type rheumatoid factor (RF-IgM) quantification reagent.
4 . 請求の範囲第 1 項または第 2項に記载する 自 己免疫疾患抗体定 量方法において、 前記マ ウス 自 己抗体定量用試薬が抗マ ウ ス一本鎖 D N A (抗 s s D N A ) 定量用試薬または抗マ ウ ス二本鎖 D N A (抗 d s D N A ) 定量用試薬である こ と を特徴とする 自 己免疫疾患抗体定量 方法。  4. The method for quantifying an autoimmune disease antibody according to claim 1 or 2, wherein the mouse autoantibody quantification reagent is used for anti-mouse single-stranded DNA (anti-ssDNA) quantification. A method for quantifying an antibody to an autoimmune disease, which is a reagent for quantification of anti-mouse double-stranded DNA (anti-ds DNA).
5 . 請求の範囲第 1 項ない し第 4項のいずれか 1 項に記载する 自 己 免疫疾患抗体定量方法において、 前記自 己免疫疾患抗体定量方法が標 準抗体曲線を用いて比較定量する こ と を特徴とする 自 己免疫疾患抗体 定量方法。  5. The method for quantifying an antibody for an autoimmune disease according to any one of claims 1 to 4, wherein the method for quantifying an antibody for an autoimmune disease performs comparative quantification using a standard antibody curve. An autoimmune disease antibody quantification method characterized by the above.
6 . 自 己免疫疾患抗体定量用試薬がマ ウ ス リ ゥマチ因子定量用試薬 またはマ ウス 自 己抗体定量用試薬である こ と を特徴とする 自 己免疫疾 患抗体定量用試薬。 6. An autoimmune disease antibody quantification reagent, wherein the autoimmune disease antibody quantification reagent is a mouse rheumatoid factor quantification reagent or a mouse autologous antibody quantification reagent.
7 . 請求の範囲第 5項に記載する 自 己免疫疾患抗体定量用試薬にお いて、 前記マ ウス リ ゥマチ因子定量用試薬がマウス I g G型リ ゥマチ 因子定量用試薬またはマ ウス I g M型 リ ゥマチ因子定量用試薬である こ と を特徴とする 自己免疫疾患抗体定量用試薬。 7. The reagent for quantifying an antibody for an autoimmune disease according to claim 5, wherein the reagent for quantifying a mouse rheumatoid factor is a reagent for quantifying a mouse IgG G-type rheumatoid factor or a mouse IgM. An autoimmune disease antibody quantification reagent, characterized in that it is a reagent for quantifying rheumatoid factor.
8 . 請求の範囲第 5 項に記載する 自 己免疫疾患抗体定量用試薬にお いて、 前記マ ウス 自 己抗体定量用試薬がマウス抗 s s D N A定量用試 薬またはマ ウス抗 d s D N A定量用試薬である こ と を特徴とする 自 己 免疫疾患抗体定量用試薬。  8. The autoimmune disease antibody quantification reagent according to claim 5, wherein the mouse autoantibody quantification reagent is a mouse anti-ssDNA quantification reagent or a mouse anti-ds DNA quantification reagent. An autoimmune disease antibody quantification reagent, which is characterized in that:
9 . ィ ム ノ グロ ブ リ ン分画固相化プレー ト と 、 マ ウス 自 己抗体検出 用標識抗体 (第二抗体) と 、 標準抗体と 、 標識物発色物質と 、 発色反 応停止剤とからなる こ と を特徴とする自 己免疫疾患抗体定量用キッ ト。  9. Immobilized immobilized plate for immunoglobulin fractionation, labeled antibody (second antibody) for mouse autoantibody detection, standard antibody, labeling substance, color reaction stopping agent An autoimmune disease antibody quantification kit characterized by comprising:
1 0 . 請求の範囲第 7項に記载する 自 己免疫疾患抗体定量用キ ッ ト において、 前記自 己免疫疾患抗体定量用キ ッ 卜がマ ウ ス I g G型 リ ゥ マチ因子定量用 E L I S A キッ トである こ と を特徴とする 自 己免疫疾 患抗体定量用キッ 卜。  10. The kit for quantifying an autoimmune disease antibody according to claim 7, wherein the kit for quantifying an autoimmune disease antibody is used for quantifying a mouse IgG type rheumatoid factor. An autoimmune disease antibody quantification kit characterized by being an ELISA kit.
1 1 . 二本鎖 D N A固相化プ レー ト 、 マ ウ ス 自 己抗体検出用標識抗 体 (第二抗体) と 、 標準抗体と 、 標識物発色物質と 、 発色反応停止剤 とからなる こ と を特徴とするマウス 自 己抗体定量用キッ ト。  1 1. Double-stranded DNA-immobilized plate, mouse Autoantibody-detected labeled antibody (second antibody), standard antibody, labeled substance, and coloring reaction terminator A mouse autoantibody quantification kit characterized by:
PCT/JP2000/000394 2000-01-27 2000-01-27 Method for quantitating autoimmune disease antibody and quantification reagent and quantification kit therefor WO2001055724A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2000/000394 WO2001055724A1 (en) 2000-01-27 2000-01-27 Method for quantitating autoimmune disease antibody and quantification reagent and quantification kit therefor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2000/000394 WO2001055724A1 (en) 2000-01-27 2000-01-27 Method for quantitating autoimmune disease antibody and quantification reagent and quantification kit therefor

Publications (1)

Publication Number Publication Date
WO2001055724A1 true WO2001055724A1 (en) 2001-08-02

Family

ID=11735621

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2000/000394 WO2001055724A1 (en) 2000-01-27 2000-01-27 Method for quantitating autoimmune disease antibody and quantification reagent and quantification kit therefor

Country Status (1)

Country Link
WO (1) WO2001055724A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102323404A (en) * 2011-05-18 2012-01-18 高翔 Autoimmunity antibody detection kit and detection method
CN107525924A (en) * 2017-08-28 2017-12-29 张庆丰 A kind of autoimmune hepatic diseases antibody assay kit

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61114165A (en) * 1984-11-09 1986-05-31 Yamasa Shoyu Co Ltd Measuring method of immune complex
JPS63255662A (en) * 1987-04-13 1988-10-21 Nitsusui Seiyaku Kk Method for measuring immune complex
JPH01296163A (en) * 1987-12-28 1989-11-29 Univ California Igg rheumatoid factor test
JPH01316662A (en) * 1988-03-30 1989-12-21 Hoechst Japan Ltd Production of instrument for measuring antinuclear antibody
JPH08289780A (en) * 1995-04-20 1996-11-05 Japan Organo Co Ltd Detection of microorganism or the like, antibody used for the same and new hybridoma forming the same antibody

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61114165A (en) * 1984-11-09 1986-05-31 Yamasa Shoyu Co Ltd Measuring method of immune complex
JPS63255662A (en) * 1987-04-13 1988-10-21 Nitsusui Seiyaku Kk Method for measuring immune complex
JPH01296163A (en) * 1987-12-28 1989-11-29 Univ California Igg rheumatoid factor test
JPH01316662A (en) * 1988-03-30 1989-12-21 Hoechst Japan Ltd Production of instrument for measuring antinuclear antibody
JPH08289780A (en) * 1995-04-20 1996-11-05 Japan Organo Co Ltd Detection of microorganism or the like, antibody used for the same and new hybridoma forming the same antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Masamitsu KANAI ed., "Rinsho Kensaho Teiyou the 30th ed.", Kanehara Shuppan K.K. (1993), page 977. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102323404A (en) * 2011-05-18 2012-01-18 高翔 Autoimmunity antibody detection kit and detection method
CN107525924A (en) * 2017-08-28 2017-12-29 张庆丰 A kind of autoimmune hepatic diseases antibody assay kit

Similar Documents

Publication Publication Date Title
Benveniste et al. Correlation of anti–signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy
US20180335431A1 (en) Novel multiplex assays to diagnose or evaluate diseases or disorders in mammals
EP1884775B1 (en) Method for diagnosis of a disease involving an anti-AT1-receptor antibody
JPH06504620A (en) Method for detecting anti-RNA antibodies
WO2001055724A1 (en) Method for quantitating autoimmune disease antibody and quantification reagent and quantification kit therefor
EP2006681A1 (en) Rheumatoid arthritis test method and treating method
JP2002541457A (en) Lipopolysaccharide immunoassay and test equipment
Sirota et al. Increased anti-Sm antibodies in schizophrenic patients and their families
Fraunberger et al. Validation of an automated enzyme immunoassay for interleukin-6 for routine clinical use
Alcantara et al. Heparin in plasma samples causes nonspecific binding to histones on Western blots
Li et al. Evaluation of serum immunoglobulins concentrations and distributions in vitiligo patients
JP2006520588A (en) Therapeutic, preventive, and diagnostic agents
WO2012100599A1 (en) Use of peroxiredoxin iv in preparing in vitro diagnostic reagents for rheumatoid arthritis
Jonsson et al. Clinical implications of IgA rheumatoid factor subclasses.
JP2000214163A (en) Measuring reagent
EP1596198B1 (en) METHOD OF MEASURING OXIDIZED LDL-beta2-GPI-CRP COMPLEX
KR20200083371A (en) Information provision method for the diagnosis of meningitis
WO2018199709A9 (en) Biomarker composition for diagnosis of systemic lupus erythematosus comprising aimp1 and method for diagnosing systemic lupus erythematosus using same
Babcock et al. Transient anti-interferon autoantibodies in the airways are associated with efficient recovery from COVID-19
Bomze et al. Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies.
Li et al. Increased serum aminotransferases associated with anti-mitochondrial antibodies in systemic lupus erythematosus patients with autoimmune liver disease
JP4774513B2 (en) Diagnostic agent and diagnostic method for autoimmune disease
WO2005040798A1 (en) Method of diagnosing alzheimer’s disease
Jain et al. Role of biomarkers in health care
JP4834810B2 (en) Anti-ENA antibody measurement method and measurement kit

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 555811

Kind code of ref document: A

Format of ref document f/p: F